NAGLAZYME (Galsulfage) Logo

Not a US Resident?

NAGLAZYME is the first and only treatment for Maroteaux-Lamy syndrome (MPS VI) that replaces the enzyme that is deficient in MPS VI.¹ With NAGLAZYME, doctors can do more than just treat symptoms by helping people with MPS VI minimize the effects of the disease. NAGLAZYME has been shown to help people with MPS VI walk farther and climb more stairs in timed tests.¹

For Patients

Learn more about MPS VI and NAGLAZYME, a treatment for all patients with MPS VI.

For Caregivers

Find out about the help available to you through BioMarin Patient and Physician Support services (BPPS).

For Healthcare Professionals

Help treat MPS VI patients. Discover data and tools, plus support from BioMarin Patient and Physician Support services (BPPS).

References

NAGLAZYME [Prescribing Information]. Novato, CA: Biomarin; 2005.

IMPORTANT SAFETY INFORMATION

NAGLAZYME^® is indicated for patients with Mucopolysaccharidosis VI (MPS VI). NAGLAZYME^® has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in patients treated with NAGLAZYME^® were headache, fever, joint pain, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and ear infections. Severe reactions included swollen blood vessels, low blood pressure, difficulty breathing, respiratory distress, stopping breathing, and hives. The most common symptoms of infusion reactions included fever, chills/shakes, headache, rash and mild to moderate hives. Nausea, vomiting, elevated blood pressure, chest pain, abdominal pain, malaise, and joint pain were also reported.

Please see full prescribing information (PDF 440KB)